Announcement Summary

Entity name

PARADIGM BIOPHARMACEUTICALS LIMITED..

Announcement Type

New announcement

Date of this announcement

Wednesday April 8, 2020

The Proposed issue is:

☑ A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +Security Code	+Security Description	Maximum Number of +securities to be issued
PAR	ORDINARY FULLY PAID	26,923,077

Proposed +issue date

Thursday April 16, 2020

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

PARADIGM BIOPHARMACEUTICALS LIMITED..

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

94169346963

1.3 ASX issuer code

PAR

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

Wednesday April 8, 2020

1.6 The Proposed issue is:

☑ A placement or other type of issue

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- **+Security holder approval**
- **Court approval**
- **Lodgement of court order with +ASIC**
- **ACCC approval**
- **FIRB approval**
- **Another approval/condition external to the entity**

☑ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☑ Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☑ No

Details of +securities proposed to be issued

ASX +Security Code and Description

PAR : ORDINARY FULLY PAID

Maximum Number of +securities proposed to be issued

26,923,077

Purpose of the issue

To fund the costs of the
second Phase 3 osteoarthritis (OA) clinical
trial

Offer price details for retail security holders

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 1.30000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Oversubscription & Scale back details

May a scale back be applied to this event?
No

Part 7C - Timetable

7C.1 Proposed +issue date

Thursday April 16, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?
No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

26923077

2-Apr-20 No. of shares on issue 197,814,099

2-Apr-29 Market Cap 334m

	15% Capacity			10% Capacity			
	No. Shares	Capacity 15%	Used	Remaining	Capacity 10%	Used	Remaining
Issued Shares	197,814,099	29,672,115	1,650,000	28,022,115			(Don't qualify as Market Cap is over $300m)

Note
1 Please provide the calculation of the current capacity to issue shares under ASX Listing Rule 7.1 (15% placement capacity) or ASX Listing Rule 7.1A (additional 10% capacity).

Total current capacity 28,022,115

2 Is the Company contemplating any other initiative in the next 12 months which would have an impact upon its ASX Listing Rule 7.1 or 7.1A capacity?

No

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?
☑ No

7D.2 Is a party referred to in listing rule 10.11.1 participating in the proposed issue?
☑ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
☑ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?
☑ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?
☑ Yes

7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

5% of proceeds raised

7E.2 Is the proposed issue to be underwritten?
☑ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

NO

Part 7F - Further Information

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

☑ No

7F.2 Any other information the entity wishes to provide about the proposed issue

NO